Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,243 across all filing types
Latest filing 2024-07-09 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on July 09, 2024, has approved the allotment of 83,000 equity shares of the face value ....
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under an Employee Stock Options Plan (ESOP). It details the number of shares allotted, the increase in issued share capital, and compliance with SEBI regulations. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is an announcement of a capital change due to share allotment under ESOP. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is under 5,000 characters and is a direct announcement, not a report publication or certification.
2024-07-09 English
Copy of Newspaper Publication
Regulatory Filings
2024-07-05 English
Pursuant to Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisements pertaining to the Notice ....
Regulatory Filings
2024-07-05 English
Updates
Environmental & Social Information Classification · 95% confidence The document is titled 'Business Responsibility and Sustainability Report for the financial year 2023-2024' and is submitted pursuant to SEBI Listing Regulations. It explicitly states that it forms an integral part of the Annual Report for FY 2023-24. The content includes detailed disclosures on environmental, social, and governance (ESG) factors such as employee demographics, grievance redressal, risk management related to product quality, EHS, IT security, and other sustainability-related issues. There is no indication that this is a brief announcement or a certification letter. The length (15,000 characters) and detailed content confirm it is a full report. Given the focus on sustainability and responsible business conduct, this aligns with the Environmental & Social Information (SR) category rather than the full Annual Report (10-K) or other categories. Therefore, the document is best classified as Environmental & Social Information (SR).
2024-07-03 English
Please find enclosed the Business Responsibility and Sustainability Report for the financial year 2023-2024, which forms an integral part of the Annual Report for the financial year 2023-2024.
Environmental & Social Information Classification · 95% confidence The document is titled 'Business Responsibility and Sustainability Report for the financial year 2023-2024' and is submitted pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It explicitly states that this report forms an integral part of the Annual Report for FY 2023-24. The content includes detailed disclosures on environmental, social, and governance (ESG) factors such as employee demographics, grievance redressal, risk management related to product quality, EHS, IT security, and other sustainability-related issues. The length of the document is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The focus on sustainability and business responsibility aligns with Environmental & Social Information filings. Therefore, the document is best classified as an Environmental & Social Information (SR) report rather than a full Annual Report or a simple announcement.
2024-07-03 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a notice of the 39th Annual General Meeting (AGM) of Bliss GVS Pharma Limited scheduled for July 25, 2024. It includes details about the meeting agenda such as adoption of financial statements, declaration of final dividend, re-appointments and appointments of directors, and other resolutions to be passed at the AGM. The document references the Annual Report for the financial year 2023-2024 but does not contain the full report itself. It is a formal notice sent to stock exchanges and shareholders as per regulatory requirements. The content aligns with the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, specifically the notice and agenda. The document is lengthy (15,000 characters) and contains detailed meeting information, not just a brief announcement or a certification. Therefore, the correct classification is AGM Information (AGM-R).
2024-07-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.